Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.46 |
| ▸ | NPC1 | O15118 | 11/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4392302 | 0.74 | RAB9A (0.59) | RAB9ANPC1ALDH1A1HSD17B10PKM | |
| SCHEMBL29374931 | 0.73 | RAB9A (0.64) | RAB9ANPC1ALDH1A1HSD17B10PKM | |
| SCHEMBL170196 | 0.73 | RAB9A (0.64) | RAB9ANPC1ALDH1A1HSD17B10PKM | |
| SCHEMBL10866984 | 0.71 | RAB9A (0.61) | RAB9ANPC1ALDH1A1HSD17B10PKM | |
| SCHEMBL31365172 | 0.71 | RAB9A (0.61) | RAB9ANPC1ALDH1A1HSD17B10PKM | |
| SCHEMBL28990083 | 0.71 | RAB9A (0.61) | RAB9ANPC1ALDH1A1HSD17B10PKM | |
| Hydrochloric Acid SCHEMBL31243061 | 0.71 | ALDH1A1 (0.63) | RAB9ANPC1ALDH1A1HSD17B10PKM | |
| SCHEMBL30883993 | 0.71 | RAB9A (0.61) | RAB9ANPC1ALDH1A1HSD17B10PKM | |
| SCHEMBL31490600 | 0.71 | RAB9A (0.61) | RAB9ANPC1ALDH1A1HSD17B10PKM | |
| SCHEMBL34463709 | 0.71 | RAB9A (0.61) | RAB9ANPC1ALDH1A1HSD17B10PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071293-A1 | LIGHT-EMITTING MATERIAL COMPRISING ORTHOMETALATED IRIDIUM COMPLEX, LIGHT-EMITTING DEVICE, HIGH EFFICIENCY RED LIGHT-EMITTING DEVICE, AND NOVEL IRIDIUM COMPLEX | FUJIFILM CORPORATION (JP) | 2011-03-24 | — | — | US | disclosed |
| EP-1971357-A2 | USE OF TPP II INHIBITORS IN COMBINATION WITH GAMMA-IRRADIATION FOR THE TREATMENT OF CANCER | Oncoreg AB (SE) | 2008-09-24 | — | — | EP | disclosed |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-15 | — | — | US | disclosed |
| WO-2007080194-A2 | USE OF TPP II INHIBITORS IN COMBINATION WITH GAMMA-IRRADIATION FOR THE TREATMENT OF CANCER | ONCOREG AB (SE) | 2007-07-19 | — | — | WO | disclosed |
| EP-1797108-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS | Eldridge, Gary R. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006031943-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS | ELDRIDGE GARY R (US) | 2006-03-23 | — | — | WO | disclosed |
| EP-1121355-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-6911442-B1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-06-28 | — | — | US | disclosed |
| EP-1127057-B1 | NAPHTHYRIDINE COMPOUNDS AND THIER AZAISOSTERIC ANALOGUES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2005-05-04 | — | — | EP | disclosed |
| US-6803369-B1 | INHIBIT A BIOLOGICAL ACTIVITY OF A TOPOISOMERASE ENZYMES | SMITHKLINE BEECHAM CORPORATION | 2004-10-12 | — | — | US | disclosed |
| US-20030088100-A1 | Process for producing optically active propargyl alcohols | SUMIKA FINE CHEMICALS CO., LTD. | 2003-05-08 | — | — | US | disclosed |
| EP-1187828-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2002-03-20 | — | — | EP | disclosed |
| EP-1127057-A1 | NAPHTHYRIDINE COMPOUNDS AND THIER AZAISOSTERIC ANALOGUES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-29 | — | — | EP | disclosed |
| EP-1121355-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000078748-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000021948-A1 | NAPHTHRYDINE COMPOUNDS AND THEIR AZAISOSTERIC ANALOGUES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
| WO-2000021952-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
| EP-0039892-B1 | SUBSTITUTED PHENYL ETHERS | CIBA-GEIGY AG (CH) | 1986-12-30 | — | — | EP | disclosed |
| US-4559354-A | ADRENERGIC BLOCKING AGENTS AND STIMULANTS; CARDIOTONIC, ANTIARRHYTHMIA AND INOTROPIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
| EP-0039892-A1 | Substituted phenyl ethers | CIBA-GEIGY AG (CH) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088100-A1 | Process for producing optically active propargyl alcohols | ADH1A, ADH1C, ADH5 | RAB9A 3280/4885NPC1 1301/4885ALDH1A1 27/4885 |
| US-20110071293-A1 | LIGHT-EMITTING MATERIAL COMPRISING ORTHOMETALATED IRIDIUM COMPLEX, LIGHT-EMITTING DEVICE, HIGH EFFICIENCY RED LIGHT-EMITTING DEVICE, AND NOVEL IRIDIUM COMPLEX | IK, RPL23A, KIF23 | RAB9A 81/4885NPC1 4267/4885ALDH1A1 1000/4885 |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | RAB9A 3630/4885NPC1 968/4885ALDH1A1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.